Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Scirica MD

Benjamin Morgan Scirica MD

Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Dr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).

His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders. 

Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).

Disclosures

  • Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
  • Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience

Recent Contributions to PracticeUpdate:

  1. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors vs Other Glucose-Lowering Drugs
  2. Effect of Metformin and Lifestyle on Coronary Artery Calcium in the Diabetes Prevention Program
  3. Acute Noncardiovascular Illness in the Cardiac ICU
  4. Cardiovascular Disease and Mortality in Type 1 and Type 2 Diabetes
  5. ACC 2017: Abstract Recommendations From Dr. Ben Scirica
  6. Serial Measurement of High Sensitivity Troponin I and Cardiovascular Outcomes in Type 2 Diabetes
  7. Increased Thromboembolic Risk With Atrial Fibrillation and Type 2 Diabetes and a Role for NOACs
  8. Insulin-Requiring vs Non–Insulin Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation
  9. Percutaneous Mechanical Circulatory Support vs Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute MI
  10. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Most Read This Week

Recently Updated